Business Description
Lipocine Inc
NAICS : 325412
SIC : 2834
ISIN : US53630X1046
Total Employee Number:
14Description
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.9 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -7.09 | |||||
Beneish M-Score | -6.65 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 53.9 | |||||
3-Year EBITDA Growth Rate | 4 | |||||
3-Year EPS without NRI Growth Rate | 8 | |||||
3-Year FCF Growth Rate | 9.4 | |||||
3-Year Book Growth Rate | -30 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.21 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.99 | |||||
Quick Ratio | 9.99 | |||||
Cash Ratio | 9.78 | |||||
Days Payable | 143.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.8 | |||||
Shareholder Yield % | -70.29 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -6.74 | |||||
Operating Margin % | -605.89 | |||||
Net Margin % | -571.18 | |||||
EBITDA Margin % | -602.95 | |||||
FCF Margin % | -501.75 | |||||
OCF Margin % | -501.75 | |||||
ROE % | -65.14 | |||||
ROA % | -58.63 | |||||
ROIC % | -2619.87 | |||||
3-Year ROIIC % | -59.05 | |||||
ROC (Joel Greenblatt) % | -10193.28 | |||||
ROCE % | -69.09 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 7.88 | |||||
PB Ratio | 0.84 | |||||
Price-to-Tangible-Book | 0.84 | |||||
EV-to-EBIT | 0.3 | |||||
EV-to-EBITDA | 0.3 | |||||
EV-to-Revenue | -1.81 | |||||
EV-to-Forward-Revenue | 34.42 | |||||
EV-to-FCF | 0.36 | |||||
Price-to-GF-Value | 1.36 | |||||
| Price-to-Net-Current-Asset-Value | 0.84 | |||||
| Price-to-Net-Cash | 0.86 | |||||
Earnings Yield (Greenblatt) % | 333.33 | |||||
FCF Yield % | -47.61 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lipocine Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.719 | ||
| EPS (TTM) (€) | -1.684 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -36.58 | ||
| 3-Year Sortino Ratio | -3.45 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 3.944 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 3.944 - 3.944 | ||
| Shares Outstanding (Mil) | 8.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lipocine Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lipocine Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 35 days | ||
| Lipocine Virtual KOL Event | 2026-06-12 11:00 | 3.94 (+0.00%) | ||
| General meeting for 2026 | 2026-06-03 10:00 | 3.94 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 3.94 (+0.00%) | ||
| Annual report for 2025 | 2026-03-10 | 3.94 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-10 | 3.94 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 3.94 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-05 | 3.94 (+0.00%) | ||
| General meeting for 2025 | 2025-06-04 10:00 | 3.94 (+0.00%) |
Show
Entries
Lipocine Inc Frequently Asked Questions
What is Lipocine Inc(STU:2VT0)'s stock price today?
The current price of STU:2VT0 is €3.94. The 52 week high of STU:2VT0 is €3.94 and 52 week low is €3.94.
When is next earnings date of Lipocine Inc(STU:2VT0)?
The next earnings date of Lipocine Inc(STU:2VT0) is 2026-08-05 Est..
Does Lipocine Inc(STU:2VT0) pay dividends? If so, how much?
Lipocine Inc(STU:2VT0) does not pay dividend.
Press Release
Articles on Lipocine Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers